rev:January 15, 1997

HOME (index page)

Return (master antibody page)

Return  (cytokeratin data page)


(anti-Human and others as indicated)

RDI Divison of researchd Industries Intl  offers a wide line of  antibodies. Since no one antibody works best for all applications (neutralization, blotting, ELISA, etc), we offer many different types of antibodies to help solve this problem. Please inquire for other applications or types of antibodies not listed below.


Mab to Cytokeratin 17

cat#RDI-PRO61036     $375.00/vial

Clone Determination Ks 17.E3

Category Mouse monoclonal

Immunoglobulin Class IgG2b

Purification SpAss-Protein A

Antigen Human cytokeratin 17 of Mr 46 000

Specificity Ks 17.E3 represents an excellent marker to distinguish myoepithelial cells from luminal epithelium of various glands (mammary, sweat, salivary, bronchial, tracheal, laryngeal, esophageal) and benign from malignant forms of e.g. mammary gland tumor

Application Suitable for frozen tissue

                   Cytological material

                    Immunoblotting (Western)

NEW: Suitable for paraffin-embedded tissue when using the MICROWAVE method.

Stability At 4°C one year after reconstitution

Quantity 50 µg (lyoph.)

Polypeptide Reacting Mr 46 000 polypeptide (human cytokeratin 17)

Antigen Recognized in Species tested so far: Human, rat (Mr 46 000 polypeptide)

Reactivities on Cultured Cell lines tested so far:  HeLa, A-431

Tumors Specifically Detected Benign tumors of mammary gland; most malignant forms of mammary tumors are negative for cytokeratin 17

Working Dilution When reconstituted with 1ml distilled water, dilute further 1:10   Incubation Time 1h at RT


Guelstein V.I., Tchypysheva T.A., Ermilova V.D., Litvinova L.V., Troyanowsky S.M. and Bannikov G.A.: Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer. Int. J. Cancer 42, 147-153 (1988)

Troyanowsky S.M., Guelstein V.I., Tchypysheva T.A., Krutovskikh V.A. and Bannikov G.A.: Patterns of expression of keratin 17 in human epithelia: dependency on cell position. J. Cell Sc. 93, 419-426 (1989)

Smedts F., Ramaekers F., Troyanowsky S., Pruszcynski M., Robben H., Lane B., Leigh I., Plantema F. and Vooijs P.: Basal-cell keratins in cervical reserve cells and a comparison to their expression in cervical intraepithelial neoplasia. Am. J. Moll, I. and Moll, R.: Comparative cytokeratin analysis of sweat gland ducts and eccrine poromas. Arch Dermatol Res. 283, 300-309 (1991)

De Jong E. van Vlijmen I., van Erp P. Ramaekers F., Troyanowsky S. and Van de Kerkhof P.: Monoclonal anti-keratin 17: A useful marker for anti-psoriatic therapies. Arch. Dermatol. Res. 283, 480-482 (1991)

Wetzels R.H.W., Schaafsma H.E., Leigh I.M., Lane E.B., Troyanowsky S.M., Wagenaar S.S., Vooijs, G.P., Ramaekers F.C. S.: Type VII collagen in human lung carcinomas. Correlation with expression of keratins 14, 16, 17 and 18. Histopathology (in press)

Demirkesen C, Hoede N, Moll R: Epithelial markers and differentiation in adnexal neoplasms of the skin: an immunohistochemical study including individual cytokeratins. J Cutan Pathol 22: 518-535 (1995).

Moll R. et al.: Differenzierungsmarker bei gynäkologischen Tumoren: Methodische und diagnostische Aspekte. In: Aktuelle Aspekte der Tumorimmunologie in der Gynäkologie. W. Zuckschwerdt Verlag (1995).

For research use only. Not supplied for use in human diagnostic or therapeutic procedures

RDI Divison of researchd Industries Intl

San Jose, 95123 CA Snell ave 658


phone 408-780-0908 or (201) 584-7093

RETURN(cytokeratin page)